Outlook: British Biotech
Tuesday 16 February 1999
First there was the grand dream of creating a "New Glaxo", a whizzy pharmaceutical giant based on some unproven compounds. Then came the bitter tussle with Andrew Millar, its former chief scientist, who was sacked for examining clinical data on the company's leading products and blowing the whistle on overoptimistic statements. The corker of a row triggered two investigations by stock exchange authorities, a Parliamentary enquiry and a collapse in the share price. The faces around the boardroom table changed since then but the results have remained the same, witness yesterday's trial failure, which at least partially vindicates Dr Millar's actions.
The new men in charge claim that Marimastat can still work on other cancers and that there are nine other studies to prove it. Shareholders should be patient, they say, these are early days, give us another year. But this is asking a lot of investors who have seen the value of their shares plunge by almost 93 per cent over the past five years. After yesterday's events, there must be a serious question over the future of British Biotech.
The company has a strong balance sheet with cash of over pounds 100m. And it is only a couple of years since this company was the rising star in Britain's rapidly growing biotech sector. But given the dreadful track record and uncertain prospects perhaps the board should finally admit defeat.Would it not now be the honourable course to return the cash to the long-suffering investors and draw the curtains on this sorry tale?
- 1 I was a Woman Against Feminism too
- 2 Students offered grants if they tweet pro-Israeli propaganda
- 3 The Tory donor whose firm is one of Britain’s biggest tax avoiders - with HMRC's blessing
- 4 John Barrowman praised for Commonwealth Games opening ceremony gay kiss
Peaches Geldof cause of death: Socialite had taken fatal dose of heroin after years of addiction, inquest concludes
Vladimir Putin employs a full-time food taster to ensure his meals aren't poisoned
Peaches Geldof: Her final day – and her fatal decision
Israel-Gaza conflict: Israel may have committed war crimes, says UN human rights chief
John Barrowman praised for Commonwealth Games opening ceremony gay kiss
Malaysia Airlines MH17 crash: Vladimir Putin is given 'one last chance' to end hostilities in Ukraine
The 'scroungers’ fight back: The welfare claimants battling to alter stereotypes
The truth about conspiracy theories is that some require considering
Arizona execution lasts two hours as killer Joseph Wood left 'snorting and gasping' for air
Malaysia Airlines MH17 crash: Ukrainian military jet was flying close to passenger plane before it was shot down, says Russian officer
Malaysia Airlines MH17 crash: Massive rise in sale of British arms to Russia
iJobs Money & Business
£18000 - £20000 per annum + OTE £25K: SThree: SThree Group has been well estab...
competitive: Progressive Recruitment: This really is a fantastic chance to joi...
£40000 - £60000 per annum + BONUS + BENEFITS: Harrington Starr: CXL, Triple Po...
£60000 - £75000 per annum + BONUS + BENEFITS: Harrington Starr: Business Anal...